RobertGMakiMDPhD, FACP, FASCO

Sarcoma, Clinical Pharmacology

Sarcoma Medical Oncology, Developmental Therapeutics

Dr. Maki is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a medical oncologist with principal clinical specialization in sarcomas of soft tissue and bone, such as osteogenic sarcoma, Ewing sarcoma, GIST, leiomyosarcoma, angiosarcoma, synovial sarcoma and malignant peripheral nerve sheath tumor and other connective tissue tumors such as desmoid tumors and giant cell tumors. I participate in both the experimental therapeutic (phase 1) and sarcoma research programs, and also take part in sarcoma translational research. Offers to collaborate are always welcome.

Please see asco.org to obtain my email address. I do not check this site often. Please also see https://orcid.org/0000-0002-9853-2528 on ORCID for publications.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1998
Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992

FASCO (Fellow of the American Society of Clinical Oncology) American Society of Clinical Oncology, 2018
America's Worst Doctors Journal of Irreproducible Results, 2018
Fellow (FACP) American College of Physicians

PubMed

Surgical Management of Sarcoma Metastatic to Liver.
Brett L Ecker, Robert G Maki, Michael J Cavnar, Ronald P DeMatteo
Hematology/oncology Clinics of North America. 2025-02-01
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybr...
Claudia Giani, Abdulazeez Salawu, Silva Ljevar, Ryan A Denu, Andrea Napolitano
The American Journal of Surgical Pathology. 2025-01-01
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16

Journal Articles

TERT Promoter Mutations in Solitary Fibrous Tumor
Robert Maki, MD, Histopathology

Journal of Clinical Oncology (JCO) PodcastSeptember 30th, 2024
SHR-A1811 Showed Promise Among Patients with HER2-Expressing Solid TumorsJuly 25th, 2024
What Is Cardiac Angiosarcoma?November 29th, 2021
Join now to see all